EORTC 1508
Research type
Research Study
Full title
A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma.
IRAS ID
211576
Contact name
Susana Banerjee
Contact email
Sponsor organisation
European Organisation For Research and Treatment of Cancer (EORTC)
Eudract number
2015-004601-17
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 2 months, 1 days
Research summary
Summary of Research
This study tests a new drug, both in combination with a known treatment and alone, in people with recurrent ovarian, fallopian tube or primary peritoneal cancer. The purpose is to find out whether the drug atezolizumab (the new drug) and combinations of atezolizumab with bevacizumab (the known drug) works against these cancers and/or is safe. The study will also look at giving acetylsalicylic acid (aspirin) together with these treatments as there is some evidence to suggest that it may help the two drugs work better.
REC name
London - Fulham Research Ethics Committee
REC reference
17/LO/0985
Date of REC Opinion
21 Jul 2017
REC opinion
Further Information Favourable Opinion